ALVO

Alvotech

ALVO.US alvotech.com + Research + Basket
CIK 0001898416
ISIN LU2458332611
Employees 1,279
Phone 354 422 4500
Fiscal year end December
IPO Jun 16, 2022
Address 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
4.91
+0.16 (+3.26%)
USD · NASDAQ
52-week range
2.94
8.01
Trading at 39% of the 52-week range
Market Cap
1.67B
P/E Ratio
0.00
Forward P/E
15.24
Book Value
-0.54
Div. Yield
N/A
% Institutions
12.82%
% Insiders
59.68%

1 Year

-41.6%

3 Year

-45.4%

10 Year

-51.3%
Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Actions

Add an action for ALVO.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Vilhelm Robert Wessman Founder & Executive Chairman 1969
Ms. Lisa Graver Chief Executive Officer 1972
Ms. Linda Jonsdottir Chief Financial Officer 1978
Mr. Joseph E. McClellan Chief Operating Officer 1974
Ms. Neha Patel Chief Information Officer NA
Mr. Benedikt Stefansson Vice President of Investor Relations & Global Communications NA
Ms. Sarah Macleod Head of Global Communications NA
Ms. Kathryn Gunnarsson Senior Vice President of Global Talent & People Experience NA
Mr. Anthony M. Maffia III Chief Quality & Regulatory Officer NA
Dr. Balaji Venkataramanan Prasad M.D. Chief Strategy Officer NA

Shareholders

▼

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Intl Stock Index Inv 2.59M 0.73% ▲ 55.19% Sep 30, 2026
2 Vanguard Emerging Mkts Stock Idx Inv 2.06M 0.58% ▲ 28.20% Sep 30, 2026
3 iShares Biotechnology ETF 1.36M 0.38% ▼ 0.75% Sep 30, 2026
4 Stefnir Icelandic Growth 792.02K 0.22% ▼ 10.78% Sep 30, 2026
5 L&G Frontier Markets Eq Z USD Acc 655.19K 0.18% ▲ 0.00% Aug 31, 2026
6 Eaton Vance Glbl Macro Abs Ret Advtg I 593.15K 0.17% ▲ 0.00% Jul 31, 2026
7 Vanguard FTSE All-Wld ex-US ETF 420.53K 0.12% ▲ 52.46% Sep 30, 2026
8 iShares Genomics Immnlgy & Hlthcr ETF 300.93K 0.08% ▲ 2.84% Sep 30, 2026
9 iShares Nasdaq US Biotech ETF USD Acc 276.80K 0.08% ▲ 0.84% Sep 30, 2026
10 Schwab Emerging Markets Equity ETF™ 182.19K 0.05% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $1.67B
EBITDA: $75.73M
Book Value: $-0.54
Earnings/Share: $-0.62
Profit Margin: -36.31%
Operating Margin: -11.05%
ROA (TTM): 2.19%
ROE (TTM): 0.00%
Revenue (TTM): $494.61M
Revenue/Share (TTM): $1.68
Earnings Growth (YOY): -99.00%
Revenue Growth (YOY): -38.90%

Valuation Metrics

Enterprise Value: $2.96B
Trailing P/E: 0.00
Forward P/E: 15.24

Shares Statistics

Shares Outstanding: 356.82M
Shares Float: 140.79M
% Insiders: 59.68%
% Institutions: 12.82%
Short % Float: 3.95%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$586.32M
Cost of Goods Sold
adjust
$-235.56M
Gross Profit
subtotal
$350.76M
SG&A
adjust
$-90.95M
R&D
adjust
$-184.19M
Operating Income
subtotal
$78.21M
Other / Non-Operating Items
adjust
$-50.29M
Net Income
subtotal
$27.92M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALVO.US!